The Eye Treatment More Westmont Parents Should Know About

It was 2017, my first year of optometry school, when I first heard the words “myopia control.” I’d worn glasses since first grade and thought I understood my own nearsightedness inside and out – I’d watched my lenses get thicker and my prescription climb through my mid-childhood and late teenage years. So I was stunned to learn that eye doctors around the world had ways to actually slow that progression down. I asked my professors the same question I now hear from parents in my own clinic almost every week: “Why haven’t I heard of this before?”

What Is Myopia Control, Exactly?

Myopia, also known as nearsightedness, happens when the eye grows a little too long. Because of that extra length, light focuses just short of the retina instead of on it, so distant objects blur while close-up vision stays clear. Screen time, heavy near work, limited time outdoors, and family history all raise a child’s risk.

Myopia control (sometimes called myopia management) is a set of treatments aimed at slowing that eye growth. The treatments include specialized contact lenses, orthokeratology, atropine eye drops, and newer lens designs in glasses. The goal isn’t just a better number on the eye chart today. It’s protecting a child’s long-term eye health, since higher levels of myopia carry a greater lifetime risk of complications like retinal detachment and glaucoma.

Why This Isn’t Common Knowledge Yet?

Glasses have solved blurry vision for centuries, so it’s no surprise that “get a stronger prescription” is still most families’ first and only instinct. Research into slowing myopia goes back to the 1970s, but the field has moved quickly only in the last decade or so: orthokeratology lenses were FDA-approved in 2002, and landmark studies (ATOM, LAMP, MiSight) built a strong case for treatment, and in 2019 MiSight became the first daytime contact lens FDA-approved specifically to slow myopia progression in children. It wasn’t until 2021 that the World Council of Optometry named myopia management a global standard of care – which tells you how young this field still is, even though the evidence behind it isn’t.

Because it’s so new, myopia control hasn’t fully worked its way into routine visits everywhere. A rushed 10-to-15-minute exam at a big-box retailer rarely leaves room for a doctor to walk a family through treatment options, even when that doctor knows the research well. And plenty of clinics simply haven’t yet built the equipment, training, or scheduling model this kind of care requires. It’s a gap in how the system is set up, not a lack of good doctors – the same way any family might need a referral for a specialty concern like glaucoma.

The Insurance Piece

Here’s the honest conversation I have with parents almost daily: even a great vision plan usually won’t fully cover a myopia control treatment plan, and many cover none of it. Vision plans still mostly reimburse for the annual exam and basic glasses, while medical insurance doesn’t yet classify myopia as the progressive disease the research shows it to be. It’s a frustrating gap between the evidence and the paperwork.

The good news is that it’s genuinely moving in the right direction. Some vision plans now let material benefits apply toward myopia control contact lenses or newer options like Essilor Stellest lenses. It’s a modest step, but a real one — and it’s making this care more reachable for more families every year.

Where Things Are Headed

More optometrists are learning myopia management in school rather than after the fact. More treatment options have FDA approval. And more parents are asking the right question at the right time – not “does my child need stronger glasses again?” but “is there something we can do to slow this down?”

If your child is nearsighted, or you’re noticing their prescription creeping up year after year, that’s worth a conversation at their next eye exam. Ask specifically about myopia control – it may be the most important five minutes of the appointment.